GSK consensus stays neutral, London shares trade near the mid-range
Published on 06/25/2026 at 14:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 14:14.
GSK (GB0009252882) starts Thursday trading on the London Stock Exchange with a broadly neutral analyst view and a share price around the middle of its 52-week corridor, according to current consensus data on Investing.com.
What the consensus shows
Investing.com reports that the consensus rating for GSK is "Neutral" based on input from 19 analysts, with 5 Buy recommendations, 12 Hold ratings, and 4 Sell votes. The same overview cites an average 12-month price target of 2,076.63 pence, implying roughly 7.11 percent upside from current levels.
The updated consensus places the high estimate at 2,750 pence and the low estimate at 1,455 pence per share, outlining a broad valuation band for the FTSE 100 healthcare group. GSK’s London shares most recently traded around 1,938.78 pence, compared with a 52-week range between 1,315 and 2,282 pence, keeping the stock near the middle of its documented one-year span.
How London trading frames GSK
On the LSE, GSK’s current level corresponds to a market capitalization in the high tens of billions of pounds, with Hargreaves Lansdown quoting a market value of about £77.5 billion at a price close to 1,950 pence. At this level, the reported price-to-earnings ratio sits around 11.3 times earnings, while the dividend yield is indicated at roughly 3.4 percent based on recent distribution data.
The last cash dividend reported by Hargreaves Lansdown was 18 pence per share, with an ex-dividend date of 19 February 2026 and payment on 9 April 2026, underlining the income component that complements GSK’s pharmaceutical and vaccine portfolio. In the wider sector context, the group competes with peers such as AstraZeneca and Sanofi in global prescription medicines and vaccines, positioning GSK as a large-cap healthcare name alongside other FTSE 100 pharmaceutical constituents.
All news and analysis on the GSK shares
Further figures, news, and regulatory filings on GSK are compiled in the ad-hoc-news.de topic overview and on the company’s investor relations pages.
How GSK earns its money
GSK generates revenues primarily through prescription pharmaceuticals, vaccines, and specialty medicines, with products such as the respiratory drug Trelegy and the RSV vaccine Arexvy among its current portfolio highlights, according to company materials.[AKTUALISIEREN]
Where the shares trade today
The GSK shares (GB0009252882) last traded in London around 1,939 pence on the London Stock Exchange, with this level corresponding to a market capitalization of roughly £77.5 billion as of 2026-06-25, 13:45 London time.
Key data on the GSK shares
- Company: GSK plc
- ISIN: GB0009252882
- WKN: 940561
- Ticker: GSK
- Trading venue: London Stock Exchange
- Price (as of 2026-06-25, 13:45): 1,939 pence
- Market cap: 77.5 billion GBP (as of 2026-06-25)
- Sector / industry: Healthcare / Pharmaceuticals & Biotechnology
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
